^
    Back
    Association details:
    Biomarker:ER mutation
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Orserdu (elacestrant) (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

    Excerpt:
    ...To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients)....
    Trial ID:
    ADELA
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer Res
    Title:

    Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

    Published date:
    12/18/2019
    Excerpt:
    Elacestrant demonstrated growth inhibition in cells resistant to all three approved CDK4/6i (palbociclib, abemaciclib, ribociclib) in both ESR1 wild-type and mutant backgrounds.
    DOI:
    10.1186/s13058-019-1230-0